跳至主要内容
临床试验/NCT00197301
NCT00197301已完成1 期

Phase 1 Study to Examine the Safety and Efficacy of a Novel Liposomal Based Intranasal Influenza Vaccine

Hadassah Medical Organization2 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2005年10月最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
入组人数
200
试验地点
2
主要终点
Seroprotection

研究概览

简要总结

Influnza vaccination is highly recommended over the age of 50,but is only 50% efficatious among the elderly. A Vaccine given as a nasal spray may improve compliance and local immunity.Liposomes are lipid particles that may serve as carriers for the vaccine and together they enhance the local immune response in mice when given as nasal spray.This study aims to examine the safety and nasal and humoral responses to the nasal vaccine compared to the commercial muscular vaccine.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Single

入排标准

年龄范围
20 Years 至 95 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Healthy young(20-45years old) and elderly(65-95 years old) volunteers -

排除标准

  • Known allergy to eggs and to the flu vaccine, pregnant and breast feeding women, chronic viral carriers, recently hospitalized persons

结局指标

主要结局

Seroprotection

次要结局

  • Antibody levels

研究者

申办方类型
Other

研究点 (2)

Loading locations...

相似试验